SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW

SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW

Show other versions (1)

<p>A role of angiotensin-converting enzyme (ACE) inhibitors in cardiovascular diseases treatment and prevention is discussed. Some large randomized clinical trials are analyzed. Physical and chemical properties of drugs and its evidence base are considered among possible factors of ACE inhibit...

Full description

Bibliographic Details
Main Authors: S. R. Gilyarevskiy, V. A. Orlov, M. V. Golshmid, G. Yu. Zakharova, I. I. Sinitsina
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
ингибитор ангиотензин-превращающего фермента
профилактика
сердечно-сосудистые заболевания
периндоприл
рамиприл
трандолаприл
Online Access:http://www.rpcardio.ru/jour/article/view/699
id doaj-202a0deff3964600ba248e12f11854c4
record_format Article
spelling doaj-202a0deff3964600ba248e12f11854c42020-11-24T21:54:03ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-0171707410.1234/1819-6446-2011-1-70-74698SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEWS. R. Gilyarevskiy0V. A. Orlov1M. V. Golshmid2G. Yu. Zakharova3I. I. Sinitsina4Российская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образования<p>A role of angiotensin-converting enzyme (ACE) inhibitors in cardiovascular diseases treatment and prevention is discussed. Some large randomized clinical trials are analyzed. Physical and chemical properties of drugs and its evidence base are considered among possible factors of ACE inhibitors choice. A problem of ACE inhibitor choice is also discussed in context of secondary prevention of cardiovascular complications in arterial hypertension and after myocardial infarction. It is concluded that the choice of any drug for cardiovascular disease treatment is mainly determined by its evidence base.</p>http://www.rpcardio.ru/jour/article/view/699ингибитор ангиотензин-превращающего ферментапрофилактикасердечно-сосудистые заболеванияпериндоприлрамиприлтрандолаприл
collection DOAJ
language English
format Article
sources DOAJ
author S. R. Gilyarevskiy
V. A. Orlov
M. V. Golshmid
G. Yu. Zakharova
I. I. Sinitsina
spellingShingle S. R. Gilyarevskiy
V. A. Orlov
M. V. Golshmid
G. Yu. Zakharova
I. I. Sinitsina
SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
Racionalʹnaâ Farmakoterapiâ v Kardiologii
ингибитор ангиотензин-превращающего фермента
профилактика
сердечно-сосудистые заболевания
периндоприл
рамиприл
трандолаприл
author_facet S. R. Gilyarevskiy
V. A. Orlov
M. V. Golshmid
G. Yu. Zakharova
I. I. Sinitsina
author_sort S. R. Gilyarevskiy
title SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
title_short SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
title_full SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
title_fullStr SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
title_full_unstemmed SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
title_sort suppression of renin-angiotensin system to prevent complications of cardiovascular diseases: current "roles" distribution from clinical pharmacologist’s point of view
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2016-01-01
description <p>A role of angiotensin-converting enzyme (ACE) inhibitors in cardiovascular diseases treatment and prevention is discussed. Some large randomized clinical trials are analyzed. Physical and chemical properties of drugs and its evidence base are considered among possible factors of ACE inhibitors choice. A problem of ACE inhibitor choice is also discussed in context of secondary prevention of cardiovascular complications in arterial hypertension and after myocardial infarction. It is concluded that the choice of any drug for cardiovascular disease treatment is mainly determined by its evidence base.</p>
topic ингибитор ангиотензин-превращающего фермента
профилактика
сердечно-сосудистые заболевания
периндоприл
рамиприл
трандолаприл
url http://www.rpcardio.ru/jour/article/view/699
work_keys_str_mv AT srgilyarevskiy suppressionofreninangiotensinsystemtopreventcomplicationsofcardiovasculardiseasescurrentrolesdistributionfromclinicalpharmacologistspointofview
AT vaorlov suppressionofreninangiotensinsystemtopreventcomplicationsofcardiovasculardiseasescurrentrolesdistributionfromclinicalpharmacologistspointofview
AT mvgolshmid suppressionofreninangiotensinsystemtopreventcomplicationsofcardiovasculardiseasescurrentrolesdistributionfromclinicalpharmacologistspointofview
AT gyuzakharova suppressionofreninangiotensinsystemtopreventcomplicationsofcardiovasculardiseasescurrentrolesdistributionfromclinicalpharmacologistspointofview
AT iisinitsina suppressionofreninangiotensinsystemtopreventcomplicationsofcardiovasculardiseasescurrentrolesdistributionfromclinicalpharmacologistspointofview
_version_ 1725869314554200064

Similar Items